Prevail Therapeutics was acquired by Eli Lilly and Company, and is now a wholly owned subsidiary of Eli Lilly.
For information please visit www.lilly.com
Leveraging recent breakthroughs in human genetics and transformative successes of AAV-based gene therapy, our goal is to create disease-modifying treatments that dramatically improve the treatment of neurodegenerative diseases in genetically-defined patient populations.
We are developing a broad pipeline of gene therapies for neurodegenerative diseases with high unmet medical need. Our lead programs include PR001 and PR006. PR001 is a potentially disease-modifying, single-dose AAV9 gene therapy delivering the GBA1 gene. PR001 is currently in Phase 1/2 clinical trials for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). PR006 is a potentially disease-modifying, single-dose AAV9 gene therapy delivering the GRN gene. PR006 is currently in a Phase 1/2 clinical trial for patients with frontotemporal dementia with GRN mutations (FTD-GRN). We are also conducting preclinical studies of PR004 for the treatment of synucleinopathies and developing a broad pipeline of potentially disease-modifying AAV gene therapies for the potential treatment of a range of neurodegenerative diseases with high unmet medical need.